Lunaphore expands flexible spatial biology offering with the launch of secondary antibodies for COMET™
LAUSANNE, Switzerland – March 7, 2023 – 4:00 pm (CET) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, announced today the launch of its secondary antibodies portfolio. Lunaphore provides the necessary components to unlock the full potential of spatial biology, from instrumentation to secondary antibodies for detection as well as other required reagents.
Lunaphore’s COMET™ is the only fully automated, high-throughput, hyperplex platform with superior tissue profiling capabilities, facilitating the analysis of 40 different spatial markers per run on a tissue slide. With the introduction of the secondary antibodies portfolio, the company continues to empower researchers to perform successful spatial biology experiments by providing ready-to-use secondary antibodies on the COMET™ platform, minimizing variability.
Lunaphore secondary antibodies have been conjugated to Alexa Fluor™ Plus, comprising key features to yield optimal staining and image quality on COMET™. The Lunaphore pre-adsorbed antibodies ensure low species cross-reactivity. They undergo stringent quality control measures to provide lot-to-lot consistency and integrate into existing experiments with ease to allow high-quality and reproducible results.
“It is critical to listen to our customers: we strive to enhance our product offering and versatile capabilities to ensure that new services integrate seamlessly into existing workflows while providing the highest level of confidence,” said Déborah Heintze, Chief Marketing Officer at Lunaphore. “The new secondary antibody kits have been extensively tested to continue delivering the strong stainings and powerful insights that our customers have come to expect. As we expand Lunaphore’s portfolio, we aim to be a vital partner and provider of the best instruments, secondary antibodies, and more so researchers can focus on addressing pressing scientific questions.”
To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
To learn more about the secondary antibodies portfolio, please visit: https://lunaphore.com/secondary-antibodies/
To learn more about Lunaphore, please visit: https://lunaphore.com/
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.
COMET™ is a fully automated, sequential immunofluorescence (seqIF™) instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of 40 different spatial markers per automated run on a tissue slide. COMET™ has a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology in areas such as immuno-oncology, neuroscience, and infectious diseases. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
For further information contact:
Lunaphore Corporate Communications
Email: [email protected]